- Global News Feed
- Alabama Stem Cells
- Alaska Stem Cells
- Arkansas Stem Cells
- Arizona Stem Cells
- California Stem Cells
- Colorado Stem Cells
- Connecticut Stem Cells
- Delaware Stem Cells
- Florida Stem Cells
- Georgia Stem Cells
- Hawaii Stem Cells
- Idaho Stem Cells
- Illinois Stem Cells
- Indiana Stem Cells
- Iowa Stem Cells
- Kansas Stem Cells
- Kentucky Stem Cells
- Louisiana Stem Cells
- Maine Stem Cells
- Maryland Stem Cells
- Massachusetts Stem Cells
- Michigan Stem Cells
- Minnesota Stem Cells
- Mississippi Stem Cells
- Missouri Stem Cells
- Montana Stem Cells
- Nebraska Stem Cells
- New Hampshire Stem Cells
- New Jersey Stem Cells
- New Mexico Stem Cells
- New York Stem Cells
- Nevada Stem Cells
- North Carolina Stem Cells
- North Dakota Stem Cells
- Oklahoma Stem Cells
- Ohio Stem Cells
- Oregon Stem Cells
- Pennsylvania Stem Cells
- Rhode Island Stem Cells
- South Carolina Stem Cells
- South Dakota Stem Cells
- Tennessee Stem Cells
- Texas Stem Cells
- Utah Stem Cells
- Vermont Stem Cells
- Virginia Stem Cells
- Washington Stem Cells
- West Virginia Stem Cells
- Wisconsin Stem Cells
- Wyoming Stem Cells
- Cell Medicine
- Cell Therapy
- Gene therapy
- Genetic Engineering
- Genetic medicine
- HCG Diet
- Hormone Replacement Therapy
- Human Genetics
- Integrative Medicine
- Molecular Genetics
- Molecular Medicine
- Nano medicine
- Preventative Medicine
- Regenerative Medicine
- Stem Cells
- Stell Cell Genetics
- Stem Cell Research
- Stem Cell Treatments
- Stem Cell Therapy
- Stem Cell Videos
- Testosterone Replacement Therapy
- Testosterone Shots
Category Archives: Maryland Stem Cells
A Look Inside A Termite’s Gut Wins The 11th Annual Nikon Small World in Motion Competition – PRNewswire
Posted: August 18, 2021 at 2:39 am
Fabiancaptured this video using a research microscope from the 1970s, utilizing polarized light. He aimed to visually illustrate the symbiotic relationship between termites and these particular protists, to help audiences better understand the unseen role they play in our natural world. Fabian meticulously created an environment with a pH, chemical composition and temperature suited to keep the symbiontsalive. These symbionts are difficult to film due to their sensitivity to light and oxygen, and any slight changes to their environment can cause both the insect and the protists in its gut to perish.
"The most challenging part of capturing this video was finding the right solution for the creatures themselves," said Fabian. "I tried a lot of methods, even preparing my own saline solution. They're very sensitive to oxygen, so I had to remove as much gas from the solution as possible. It was very tricky, and I had to work fast. The video you're seeing is the result of months of trial and error, a lot of research and perseverance."
Protists are a wide and highly diverse array of single-celled organisms, but those featured in the winning video have formed a relationshipwith termites to process the cellulose they eat and help them derive nutrition from it and cycle carbon back into the soil. "Protists, while largely unknown to the generalpublic, are indeed the most abundant creatures on the planet," said Fabian. "There is a significant gap in our understanding aboutthese termite symbiontsand how this unique evolutionary relationship developed with its host, making it well worth exploring and presenting."
Fabian added, "The beautiful thing is that easy access to modern imaging and the internet has allowed those with an interest in microscopy to share their discoveries globally, across all boundaries of culture, language and age. The world is so small, and we can connect easily with anyone across the globe." Fabianhopes that his video will spark greater interest in Protists, as well as inspiring and encouraging more young peoples interested in STEM subjects.
"We're living in an amazing time when we have the ability to capture and share high-quality scientific imagery," said Eric Flem, Communications Manager, Nikon Instruments. "This year's winning entry highlights the power that microscopy has to connect like-minded individuals, educate others using engaging visuals, and spread scientific knowledge to the general public"
Second place was awarded to Dr. Stephanie Hachey and Dr. Christopher Hughes for their time-lapsed fluorescence microscopy video of an engineered human micro-tumor forming and metastasizing. In order to capture this video, stromal cells and cancer cells were introduced into a microfluidic platform under dynamic flow conditions and placed into a customized CO2 and humidity-controlled chamber. The platform was imaged every 15 minutes for 10 consecutive days.
The 2021 judging panel included:
For additional information, please visit http://www.nikonsmallworld.com, or follow the conversation on Facebook, Twitter @NikonSmallWorld and Instagram @NikonInstruments.
NIKON SMALL WORLD IN MOTION WINNERS
1st PlaceFabian J. WestonPennant Hills, New South Wales, AustraliaMicrofauna in a termite gutPolarized Light10X, 20X & 40X (Objective Lens Magnification)
2nd PlaceDr. Stephanie Hachey & Dr. Christopher HughesUniversity of California, IrvineDepartment of Molecular Biology and BiochemistryIrvine, California, USA10-day time-lapse of an engineered human micro-tumor forming and metastasizing. Vessels (red) support the growing tumor (blue).Confocal, Fluorescence10X (Objective Lens Magnification)
3rd PlaceAndrei SavitskyCherkassy, UkraineWater flea (Daphnia pulex) giving birth to cubsDarkfield4X (Objective Lens Magnification)
4th PlaceDr. Alexandre DumoulinUniversity of ZurichDepartment of Molecular Life SciencesZurich, SwitzerlandCommissural axons turning in an organized manner just after having crossed the midline of the central nervous systemConfocal40X (Objective Lens Magnification)
5th PlaceDr. Sachie Kanatani & Dr. Photini SinnisJohns Hopkins Bloomberg School of Public HealthDepartment of Molecular Microbiology and ImmunologyBaltimore, Maryland, USAInfected mosquito salivating fluorescently-labeled malaria parasites Confocal10X (Objective Lens Magnification)
Sophie-Marie Aicher & Dr. Delphine PlanasInstitut Pasteur ParisDepartment of VirologyParis, le-de-France, FranceSARS-CoV-2 infection triggering cell fusion and cell death (red) in bat (Myotis myotis) brain cellsFluorescence, Phase Contrast20X (Objective Lens Magnification)
Richard AlbrechtAltenstadt, Bavaria, GermanyMosquito (Culex pipiens) laying eggsReflected Light, Stereomicroscopy5X - 20X (Objective Lens Magnification)
Bernard Allard & Didier BarbetClub Franais de MicroscopieSucy-en-Bry, FranceHydra and Trichodina parasitesBrightfield4X - 20X (Objective Lens Magnification)
Giulia L. M. Boezio & Dr. Radhan RamadassMax Planck Institute for Heart and Lung ResearchDepartment of Developmental GeneticsBad Nauheim, Hessen, Germany3-day old zebrafish (Danio rerio) showing the beating heart, aorta, and connecting vessels (endothelial cells: white; blood cells: red)Confocal40X (Objective Lens Magnification)
Dr. Dylan T. BurnetteVanderbilt University School of MedicineDepartment of Cell and Developmental BiologyNashville, Tennessee, USAEpithelial cells in cultureDifferential Interference Contrast (DIC)60X (Objective Lens Magnification)
Dr. Dylan T. BurnetteVanderbilt University School of MedicineDepartment of Cell and Developmental BiologyNashville, Tennessee, USADNA during cell division and deathConfocal60X (Objective Lens Magnification)
Dr. Nan-Shan Chang, Pei-Yi Chou, Yu-An Chen & Chen-Yu LuNational Cheng Kung UniversityDepartment of Molecular MedicineTainan, TaiwanMetastatic 231 breast cancer cells meet with L929 fibroblastsBrightfield10X (Objective Lens Magnification)
Yen Fook ChewWoodend, Waimakiriri, New ZealandA cladoceran (Chydorus sp.) moving on the cocoon of a caddisfly nymph prompting a reaction. The caddisfly spends its youth as an aquatic insect before leaving the water to become airborne.Darkfield4X (Objective Lens Magnification)
Yen Fook ChewWoodend, Waimakiriri, New ZealandHaving ingested nine Chydrorus, this oligochaete worm (Chaetogaster sp.) is having difficulty with the tenth, expelling it twice. This worm feeds by powerful suction rather like a vacuum cleaner.Darkfield, Polarized Light4X (Objective Lens Magnification)
Momir FutoRudjer Boskovic InstituteDivision of Molecular Biology / Laboratory of Evolutionary GeneticsZagreb, Grad Zagreb, Croatia5-day time-lapse of Bacillus subtilis biofilm growth and developmentStereomicroscopy0.65X (Objective Lens Magnification)
Dr. Jasmin Imran Alsous, Jonathan Jackson & Dr. Adam MartinSimons Foundation Flatiron InstituteCenter for Computational BiologyCambridge, Massachusetts, USANurse cells (cyan) contract and shrink in response to myosin waves (red) as they transport their contents to the egg cell in a fruit fly egg chamber.Confocal40X (Objective Lens Magnification)
Dylan Jones & Dr. Brian AtkinsonUniversity of NottinghamDepartment of Plant ScienceSutton Bonington, Leicestershire, United KingdomLaser ablation and reconstruction of pearl millet crown root Laser Ablation Tomography5X (Objective Lens Magnification)
Martin Kaae KristiansenMy Microscopic WorldAalborg, Nordjylland, DenmarkTardigrade showing individual muscle strands (muscles glow with different colors depending on the orientation to the light source)Polarized Light10X (Objective Lens Magnification)
Ana Gabriela MadrigalMcGill UniversityInstitute of ParasitologySte-Anne-de-Bellevue, QC, CanadaNeutrophils (type of white blood cell) rolling through mouse blood vesselConfocal20X (Objective Lens Magnification)
Dr. Alvaro MigottoCentro de Biologia MarinhaSo Sebastio, So Paulo, BrazilSea cucumberDarkfield1.6X - 40X (Objective Lens Magnification)
Danielle Parsons & Alan deHaasWonder ScienceLos Angeles, California, USATwo liquid crystals crystallizing on the same microscope slidePolarized Light20X (Objective Lens Magnification)
Dr. Eric Peterman & Jeff RasmussenUniversity of WashingtonDepartment of BiologySeattle, Washington, USADebris from degenerating axons (magenta) engulfed by an immune cell (cyan) in zebrafish (Danio rerio) skin Confocal25X (Objective Lens Magnification)
Wojtek PlonkaKrakow, Malopolskie, PolandTen day time-lapse of moss growthImage Stacking6X (Objective Lens Magnification)
Wojtek PlonkaKrakow, Malopolskie, Poland10-day time-lapse of Lobelia pendula seed developmentImage Stacking6X (Objective Lens Magnification)
Martina Schaettin & Dr. Fabian F. VoigtUniversity of ZurichDepartment of Molecular Life SciencesZurich, SwitzerlandFly-through of the nervous system of a 7-day old chicken embryoLight Sheet0.8X - 4X (Objective Lens Magnification)
Dr. Shinji ShimodeYokohama National UniversityManazuru Marne Center (MMCER)Manazuru-machi, Kanagawa, JapanPelagosphaera larva (planktonic larval stage) of sipunculid worms (peanut worms)Stereomicroscopy60X - 120X (Objective Lens Magnification)
Francesca StranoVictoria University of WellingtonSchool of Biological SciencesWellington, New ZealandSea slugsStereomicroscopy6X (Objective Lens Magnification)
Maria F. Ullo & Jeremy S. LogueAlbany Medical CollegeDepartment of Regenerative and Cancer Cell BiologyAlbany, New York, USAFluorescently tagged actin filaments flowing within a blebbing human melanoma cellDeconvolution, Fluorescence60X (Objective Lens Magnification)
Gaurav Upadhyay, Vedant Kumar & Dr. Rajneesh BhardwajIIT BombayDepartment of Mechanical EngineeringMumbai, Maharashtra, IndiaWater droplet bouncing over a superhydrophobic cantilever beamBrightfield7X (Objective Lens Magnification)
Wim van EgmondMicropolitan MuseumBerkel en Rodenrijs, Zuid Holland, NetherlandsMudflat diatomsBrightfield, Darkfield, Differential Interference Contrast (DIC), Reflected Light5X, 16X, 25X (Objective Lens Magnification)
Thomas A. Zangle & Soorya PradeepUniversity of UtahDepartment of Chemical EngineeringSalt Lake City, Utah, USA5-day time-lapse of rat hippocampal neurons showing development of networks and interconnections. Contrast enhanced to highlight neurites.Quantitative Phase Microscopy20X (Objective Lens Magnification)
About Nikon Small World Photomicrography CompetitionThe Nikon Small World Photomicrography Competition is open to anyone with an interest in photography or video. Participants may upload digital images and videos directly at http://www.nikonsmallworld.com. For additional information, contact Nikon Small World, Nikon Instruments Inc., 1300 Walt Whitman Road, Melville, NY 11747, USA, or phone (631) 547-8569. Entry forms for Nikon's 2021 Small World and Small World in Motion Competitions are available at https://enter.nikonsmallworld.com/
About Nikon Instruments Inc. Nikon Instruments Inc. is the US microscopy arm of Nikon Healthcare, a world leader in the development and manufacture of optical and digital imaging technology for biomedical applications. For more information, visit https://www.microscope.healthcare.nikon.com/ or contact us at 1-800-52-NIKON.
SOURCE Nikon Instruments Inc.
Posted: June 6, 2021 at 1:55 am
Lies in Lancet
When the Covid pandemic erupted, 27 top virologists got together and wrote an article in the prestigious Lancet journal (19 February 20), absolving China of all blame and asserting that it was a natural zoonotic epidemic that had emerged from the wet markets of Wuhan. In the highly polarized presidential campaign in America, this scientific judgment was used to dismiss all strident claims of President Trump and his cabinet members, accusing China of generating this virus in a lab from where it appeared to have leaked out. These were then cynically branded as mere conspiracy theories.
With the heat and dust of the presidential campaign behind us, we have had time for more sober reflection and the picture that is emerging is not pretty. A number of disclosures have come under the Freedom of Information Act in the USA and the scientific community has taken a second hard look at the data. It now turns out that one of the lead authors of this defense of China in Lancet, was Peter Dasazak, head of the NGO, the Eco Health Alliance. He had a serious conflict of interest which should have disqualified him from commenting on issues pertaining to the Wuhan institute of Virology (WIV). It turns out that during President Obamas tenure, the gain of function research was being undertaken in some virology labs in US. This had been initiated by DARPA as part of its pre-empt programme (to anticipate nature and hostile counties) by producing souped up viruses (before nature could) and developing medicines and vaccines to counter them. Primary establishment was the US Army Research Institute of Infectious Diseases at Fort Detrick, Maryland. There were serious concerns of leakage and all such research was halted for two years. It was then that Dr Fauci of the NIH decided to offload all such research to foreign countries thru NGOs. As part of this, $3.7 million was given to Peter Dasazks Eco Health Organisation. He, along with the Chinese governments Ministry of Science and Technology, had jointly funded the gain of function research at the Wuhan institute. Subsequently, he was part of the WHO Team sent for investigations to Wuhan. He did not recuse himself and gave a second clean chit to WIV in the 30 March 21 WHO report. The lid was blown off this cover-up really by Nicholas Wades meticulously researched article in the Bulletin of Atomic Scientists, one of the most prestigious scientific journals. He pointed out how Maj Gen Shi Zheng li, who was heading the WIV, had cooperated with Prof Ralph Baric of the North Carolina University for gain of function research on bat corona viruses. In fact, he had tutored her on the technique of serial passage through cell cultures that make the modified virus look natural. With Prof Barics help, she had been able to splice a SARs hook molecule on to the backbone of a bat coronavirus so that it would now attach on to the cells of human air ways in November 2015 itself.
Chinese Miltary Interest in Bio Warfare
Back in 1999, I was serving in the Military Operations Directorate with NBC (Nuclear Chemical and Biological Warfare) as part of my charter. We were jolted to see a Book on Unrestricted Warfare by two Chinese Senior Colonels-Quiao Liang and Wang Xiangsi (they later rose to be generals). It was on how China could take on and defeat a super power like the USA by waging a no-holds-barred conflict that involved a multitude of means, including military and non- military. Non-military means included terrorism, biological warfare, cyber warfare, information warfare, economic warfare and a host of others. The aim was to bring the enemy to his knees, without a shot being fired, by non- contact warfare
This was followed up by a book War for Power by Guo- Jeiwi, a military researcher, in 2010. This openly talked of a new concept of war with biological characteristics. Further books followed, including one by Lt Gen Zhang Zibu, who openly talked of weaponising the virus.
Official Military Doctrine: All these books by individual military officers could be taken as mere kite flying or veiled threats. However, in 2017, China updated its official military doctrine enshrined in the science of Military Strategy. This updated edition added a new chapter on biological warfare, titled Biology as a Domain for Military Strategy. China is a signatory to the biological warfare convention banning such weapons. How then could China include bio-warfare in its official doctrine? The world should have protested loudly, but it did not.
The Smoking Gun document, however, had been written even earlier. In 2015, Xu Dezhong, a senior Chinese Airforce virologist, had led a team of 18 scientists and authored an exhaustive study on biological warfare. Their findings were presented to the CMC and the highest leadership in China over 24 sessions- in itself a clear indication of the overwhelming significance allocated to this subject. This document actually explains what precisely has happened since then. Some of the crucial findings/ recommendations of this study merit highlighting in detail:
This report clearly stated that the SARS virus was a genetically engineered virus specifically designed to target China. This was startling and indicates a siege mentalitya deep seated Chinese perception that it is the victim of biological war. Ergo sum, China is fully justified in retaliating in kind. Such a Chinese mindset in itself is dangerous and has possibly precipitated the indiscriminate Wuhan virus release.
This study spoke of how the new found technique of freeze drying micro-organisms has enabled storage of bio-war agents. These can subsequently be aerosolized whenever a biological warfare attack has to be mounted. Such an attack is so easy to mount and cannot really be traced back to source. There is complete deniability in such attacks.
The study spoke of how the entire health care system in a society can be collapsed and crippled with such a biological attack. Not only will this cause mass casualties and widespread morbidity but induce tremendous psychological stress in victim countries. It can have long term disruptive impact and bring about economic collapse. Hence such bio agents are ideal to bring a country to its knees without a shot being fired. This actualizes Sun tzus axiom of subduing the enemy without fighting. At the very least it would set up the target country for a follow up military strike to exploit the severe disarray and disruption.
Chinese Biological War Preprations
The unfortunate fact is China did not stop at theorizing and writing about bio-warfare. It took active and concerted steps to create this capability in a useable form. Consider the following:
There are two virological labs in Wuhan itself. The WIV lab was set up with French assistance as a level Four facility. It is headed by two PLA general rank officersMaj Gen Shi Zhengli (famed as Chinas bat woman and worlds leading expert on bat corona viruses) and Maj Gen Cao wei (who had served in Africa and dealt with MERS and Ebola epedemics).The very fact that Chinas virological labs are headed by military officers, indicates the military dimension of their programs.
The trail goes back to 2012 when six Chinese miners in a disused Copper mine died of Pneumonia with lung patches similar to Covid. Gen Sheng Li rushed teams there and collected and studied samples from 276 bats in 2013. They published findings in2016 and identified the bat corona virus strain as RaBTCov/ 4991. (This was later found to be the same as the infamous strain Ra TG 13 which has 96.2% match with the genome sequence of Covid-19 virus.)
In 2015, Gen Shi Zheng li had written four papers on how the SARS hook virus could be spliced on to the bat corona backbone to make it a highly lethal and communicable virus as part of gain of function.
She was mentored by Prof Ralph Baric of the University of North Carolina in USA. Not only did he help her with this gain of function research, he also taught her to do it via serial passage through cell cultures to mask it and make it look like a natural virus. Nicholas Wade has disclosed this. By Nov 2015 this souped up virus was ready in the Wuhan institute of Virology. This research continued through 2016. In 2017 an American team that had visited Wuhan, warned of lax protocols there and how these very dangerous pathogens stored there could leak out. Contact between US and Chinese scientists seemed to have declined steeply thereafter and Dr Sheng lis four papers were suddenly taken off the net. The whole program was suddenly made quite opaque.
A recent study by a UK and Norway based duo of Micro- biologists called Dr Anges Dalgaleh and Berger Soransen has now quite conclusively proved that that the Wuhan coronavirus is not a natural virus but is definitely lab engineered. They noted that the SARS hook molecule had been spliced on to the backbone of the bat carona virus. This hook molecule had four positively charged amino acids which made them easily attach to negatively charged human cells and become far more infectious. Here is the catch. Positively charged ions repel each other. Hence in natural organisms finding two such positively charged amino acids in a row is difficult. Three is a rarity. Four in a row gives the show awayit is definitely a lab-engineered virus.
Holes in the Zoonotic Theory: The Zoonotic theory that this pandemic emerged from the Wuhan wet market is full of holes. To start with No bats are sold in the Wuhan wet markets. The nearest they are found is in the caves of Nanjing some 550 km away. The only people who went there to collect bats from Nanjing and Yunan caves were six operatives from the WIV. Three of them died in autumn 2019 of a disease with remarkably similar symptoms to Covid. All such viruses from animal vectors usually come thru an intermediary host. Thus SARS came via bats to civet (cats) to humans. This link was discovered in a matter of days. MERS came to man from bats via camels to humans. This link was discovered in just 4 months. Its over 18 months since the Covid pandemic hit us, till now there is no trace of the intermediary host. The reason is simple. There is none because it is not a natural virus. It was most deliberately engineered in a lab.
What Really Happened at Wuhan? Circumstantial Evidence
We have sufficient circumstantial evidence that by 2015, the top Chinese leadership was convinced that it was the victim of biological warfare via the SARS genetically engineered virus. Right or wrong is immaterial, what matters is the strong perception and siege mentality. We find that in 2015 itself, energetic steps being taken in WIV to weaponise the bat corona virus isolated from the defunct Copper mines. This gain of function virus was ready by November 2015 and China was ready to strike back! The updated edition of the official PLA doctrine in 2017 had a whole new chapter on biological warfare .Bio war was now official doctrine of PLA. Meanwhile, Donald Trump had become the president of USA and with great clarity, he identified China as the main adversary and challenger. He took very proactive steps to contain the rise of a highly aggressive China. He put tremendous pressure via arming Taiwan, stoking/ highlighting unrest in Hongkong, Xinjiang and Tibet and then via an all out Trade war. The US Navy pushed back strongly in Taiwan straits and South and East China seas.
Thus, by 2019 China was under tremendous pressure. In September 2019, the military games took place in Wuhan and later Zhao lijian, official spokesperson of Chinese Foreign ministry, accused the US Special Forces of spreading the coronavirus in Wuhan under cover of the games. The veracity of the charge is another matter. I am highlighting the Chinese perceptions that could have become motivations for action. There are some media reports that in 2019, China made vaccination compulsory for all citizens. US intelligence reports indicate that in November 2019, three Chinese workers in the WIV had fallen sick with symptoms very similar to the Covid outbreak. The first Covid case was acknowledged only on 8 December 2019. Thereafter, starts a deliberate trail of obfuscation and deliberate suppression of information. Whistleblower doctors and researchers were killed or jailed; even in late December, WHO was being told that this disease was not communicable from human to human. Dr Guissepe, a top Italian Micro biologist, tells us that the PLA was given charge of containing the virus in Wuhan. For a nation supposedly taken by surprise, they did an amazingly efficient job. Beijing, a 1000 km away, and Shanghai, just 800 km away, were unscathed. However, 20 flights a day from Wuhan to New York and a similar number to Europe and other destinations were allowed to continue unchecked.
On 20 January 2020, the WIV filed a use patent for Remdesivir, the much-touted cure for corona. To file a use patent, you have to test at least for two/three months. Thus, the Chinese knew all about Covid from at least November 2019 onwards, if not earlier. Yet, deliberate suppression of information continued. In fact, in February 20, over two months after acknowledgement of Covid, the Chinese Foreign Minister was calling upon all neighbouring countries to keep their borders open (ostensibly for prestige reasons). Whether the release was accidental or deliberate, China was certainly doing everything to spread the coronavirus and weaponise its release.
Accident or Staged Accident?
We now come across a strange coincidence. By 8 December 2019, the first Covid patient had been acknowledged in Wuhan. On 28 December 2019, the Chinese Aircraft Carrier Liaoning had sailed out into the Taiwan straits and East and South China seas. The Chinese Navy and Air Force had started a series of muscular exercises against Taiwan, Japan and South China sea countries Two US Nuclear Powered Aircraft carriers had to be withdrawn from the Pacific as their crews were infected with Covid. China hurriedly readied and deployed its second Air craft carrier and became dangerously provocative, especially with its Air Force incursions into Taiwans AIZ.
In end Mar-Apr 2020, China staged two mechanized divisions from Xinjiang and started Incursions against India in Ladakh. Does a country surprised suddenly by a pandemic start war like moves against all its neighbours concurrently? Or does it hunker down to protect its population and deal with the pandemic? There is something seriously sinister in this juxtaposition of the pandemic and very aggressive military moves on all fronts. It almost smacks of an attempt to exploit a biological strike. In World War II, Japan and Germany had started invasions of China and Poland with staged incidents. That leads to the uncomfortable questionwas the Wuhan accidental release, a staged accident? The world is now veering around to the view that what happened in Wuhan was an accidental release. I have pointed out to a whole lot of circumstantial evidence that seems to suggest that given Chinas fear psychosis, it could well have been a Staged Accident. Such actions stem from perceptions and Chinas clear perception since 2015 has been that it has already been attacked by biological weapons- retaliation is therefore justified.
Where do we go from here?
There is a sadly capitulationist mindset, that the world can do nothing to China, so let sleeping dogs lie. I would contest that strongly. Phillipines had taken China to the ICJ and won its case on the South China Sea dispute. China ignored the ICJ verdict with contempt, but has had to pay a heavy price with the US Navy and other Quad nations Carrier battle groups steaming into South China Sea to strongly contest the restrictions on freedom of navigation in a big way.
The IAEA is the worlds watchdog on nuclear proliferation. It has strong teeth to carry out intrusive inspections of nuclear reactors even in rouge nations. We need to rework the Biological Warfare Convention and create international watch dog bodies to carry out intrusive inspections of virological laboratories in all countries.
The world cannot afford to let China get away scot-free on Covid. 167 million people have been infected and 3.5 million are dead. 3 lakh citizens have died in India itself. China and other nations (including Pakistan) will have to deterred if such mayhem has to be stopped. The world needs to get to gather and name and shame as the first step. Concerted multi-domain pressure is called for to deter China in a credible fashion.
Go here to see the original:
What really happened in Wuhan? - The Sunday Guardian Live - The Sunday Guardian
Posted: December 20, 2020 at 4:57 pm
Winning the Inventor Pitch Award at UMD Bioscience Day
Telugu and his team pitched this work at UMD Bioscience Day on behalf of his company, RBI, and received the Inventor Pitch Award and the UMD Invention of the Year Award in 2018. In order to protect the intellectual property, Telugu worked with the UMD Office of Technology Commercialization (OTC) to secure patents and open the work up for additional fundraising to carry this technology through the preclinical and clinical stages. The Maryland Stem Cell Foundation provided some funding to advance this work, and Telugu is thankful that Maryland funds technologies in the human stem cell space.
There are many terminal cases where people need some sort of an organ replacement, like organ failure and degenerative diseases that cannot be cured by drugs, explains Telugu. The traditional paradigm is to find a donor organ, but as of today there are still thousands of patients waiting for transplants, and there is no keeping up with the demand. Researchers have thought for a long time that stem cells could help solve this problem, and these stem cells have the ability to go into a specific organ as opposed to those that go into any lineage. In this case, you can differentiate the cells and place them where they are needed to help rescue a diseased organ, eliminating the need for transplant or at least buying the patient some time. Just making the human liver and collecting them early from a neonatal piglet, the hepatocyte [liver] cells alone are a $3 billion opportunity per year. And in the future, we can move into organ transplantation, first with the liver, and then looking at other organs of interest like the pancreas and lungs.
According to Telugu, this has distinct advantages over other methods that researchers are currently using to create donor organs in pigs, since the organs Telugu and his team are working with are actually of human origin and are therefore more likely to be accepted when transplanted. Transplant rejections are pretty common even between humans and humans, says Telugu, and if it is such a problem normally, you can imagine how an organ from a pig could be difficult to accept and may not essentially perform the same functions. Pig proteins may not function the same, so that remains a huge barrier for other methods that are not actually growing fully human organs like ours.
This work has the potential to solve a major problem in the treatment of organ failure and other degenerative diseases, which is what Telugu and his work is all about. Being a veterinarian by training, we always look at the problem and try to find solutions to them, says Telugu. Most animal scientists operate by looking for solutions, so integrating research and entrepreneurship to get this to the market where it is needed is essential. We are one of the few groups on the planet that are working in this space, and we have a great team of embryologists here at Maryland to do this work. We are uniquely positioned to accomplish this with both genome editing and stem cell biology expertise, and being able to prove the concept with this paper is a great first step towards our goals.
The paper, entitled Extra-embryonic endoderm (XEN) cells capable of contributing to embryonic chimeras established from pig embryos, is published in Stem Cells Reports, DOI: 10.1016/j.stemcr.2020.11.011.
Read the original post:
UMD Researchers Perform Crucial Proof-of-Concept ...
US gets more help in raging battle against COVID-19 as FDA authorizes Moderna vaccine, the second allowed for emergency use – USA TODAY
Posted: at 4:57 pm
The FDA has authorized Moderna's COVID-19 vaccine for emergency use in the U.S. The first shots of the vaccine are expected to be given Monday. USA TODAY
CAMBRIDGE, Mass. Americans will soon have access to a second COVID-19 vaccine.
Stephen Hahn, commissioner of the U.S. Food and Drug Administration, granted emergency authorization Fridayto a vaccine made by Moderna,a week after giving similar clearance to one made by Pfizer and its German collaborator, BioNTech.
His is "authorizing" rather than approving the vaccine, because longer-term research is needed to meet the full standards for approval, which officials don't want to wait for during the public health emergency.
The speedy path to authorization was possible because the agencycut through regulatory red tape,Hahnsaid at a Friday night press conference. "We worked quickly based onthe urgency of this global pandemic ... we have not cut corners."
The announcementmakesthe U.S.the first country to authorize two COVID-19 vaccines that demonstrate "clear and compelling efficacy, Dr.Peter Marks director of the Center for Biologics Evaluation and Research at the FDA said during the press conference.Marks said it isanother milestone as we work to end the COVID-19 pandemic.
The move comes a day afterthe U.S. reported its 17 millionth case of COVID-19and an independent advisory committee reviewed data from human trials of Moderna's mRNA-1273 vaccine, deciding its benefits outweighed its risks. The vaccine, according to a trial that included 30,000 volunteers,protected more than94% of recipients from active disease, without causing major safety concerns.
Trucks will begin moving the vaccine this weekend, with the first of 5.9 million already manufactured Moderna shots expected to be given on Monday.
Your vaccine questions, answered:I had COVID, should I still get vaccinated? What are the side effects? What are its 'ingredients?'
In this special edition episode of States of America, experts answer the biggest questions Americans have about the vaccine, side effects, how it's getting to you and more. USA TODAY
It's a triumphant moment for the 10-year-old Cambridge, Massachusetts, biotech companythat until nowhad never brought a product to market.
Now, both its vaccine and the one byPfizer-BioNTecharepoised to change the course of the worst pandemic in a century.
The virus that causes COVID-19 hasswept the world and particularly devastated the United States, which accounts for 4% of the world's populationbut nearly 23%of its COVID-19 cases and 19%of its deaths.
During the current winter surge, anAmerican is reported dead about every 34 seconds from the virus, and 150 are diagnosed every minute.
But it will take time to roll out vaccine across the country and the world, achieving the 70% protection from both vaccination and natural disease that experts say will be needed to stop widespread infections.
In this file photo taken on November 18, 2020 shows a syringe and a bottle reading "Vaccine Covid-19" next to the Moderna biotech company logo.(Photo: JOEL SAGET, AFP via Getty Images)
Moderna, which developed its vaccine in collaboration with government scientists,says it will be able to deliver 20 million doses of its vaccine by the end of December. Another 80 million will be available in the first few months of 2021, under a contract signed in Augustthat brought the U.S. government's direct financial backing of the companyto $2.5 billion.
"It is through the dedicated efforts of our federal scientists and their collaborators at Moderna and in academia, the clinical staff who conducted the vaccine's rigorous clinical trials, and the tens of thousands of study participants who selflessly rolled up their sleeves, that another safe and highly effective vaccine to protect against COVID-19 will soon be rolled out to the American public," Dr. Francis Collins, director of the National Institutes of Health, said Friday.
Just last week, the government closed a deal for a second 100 million doses to be delivered in the second quarter of next year, bringing taxpayers' total investment in mRNA-1273 up to$4.1 billion.
Another candidate vaccine, from Johnson & Johnson, fully enrolled its large-scale humantrial Thursdayand expects to report its first safety and effectiveness data in January.
A fourth, created by AstraZeneca and Oxford University, is a few weeks behind, and a fifth candidate, by vaccine developer Novavax ofGaithersburg, Maryland, is expected to begin its major U.S. trial shortly.
If all or most of these come through, there shouldbe plenty of vaccine by the endof next summer to cover every American who wants one.
"It's just incredible science and human achievement,"said Dr. Steven Joffe, a professor of medical ethics and health policyat the Perelman School of Medicine at the University of Pennsylvania."Not just the science that went into the vaccines, but the organizational effort to pull off those trials it's marvelous."
Although Moderna moved extremely fast, winning authorization just 11 months after beginning work on mRNA-1273, ithas been developing the technology behind its vaccinefor a decade.
The company was founded in 2010 on the banks of the Charles River, a short walkfrom the Massachusetts Institute of Technology, where one of its founders was a faculty member,and another a graduate and board member.
That MIT gradand board of trustees member, venture capitalist Noubar Afeyan,said he was intrigued at the time by the idea of making drugs inside the human body.
Messenger RNA, which the body uses to translate the DNA code into the proteins that do all the body's work, seemed like the right tool to address a whole host of medical problems, he said.
Operation Warp Speed has helped Moderna move faster in vaccine development.(Photo: JOSEPH PREZIOSO/AFP via Getty Images)
Afeyan saidhe likes to start companies with big ideas that seem like science fictionand then "take the fiction out" by finding the science to make it real.
Moderna was initially namedLS18 to indicate it was the 18th life sciences company Afeyan had started. (He's lost track of whether his latest company is LS79 or LS80, he said.) The idea was seeded by a stem cell scientist at nearby Harvard University, Derrick Rossi, who was trying to commercialize his research using the body's most versatile cells to make medicines.
Afeyan said it was a provocative concept. But by May of the following year, when the company was officially launched as Moderna, they had dropped the idea of using stem cells, which Afeyan said were too unstable in the body, and focused instead on messenger RNA (hence the name ModeRNA).
Messenger or mRNA is the body's own delivery system, taking "messages" from the DNA code in the cell's nucleus to a protein manufacturing center.
Where's the COVID-19 vaccine? Who's been vaccinated?Here's how we'll know.
These proteins direct every activity of life, so figuringout how to make them on demand could help people who suffer severe diseases because their bodies make faulty proteinsas with sickle cell disease, cystic fibrosis and myriad rare diseases. Such proteins could alsoprime the immune system to target cancer cells, or infectious diseases.
Afeyan and his collaborators wanted to tackle this whole range of medical challenges.
But first, they needed a CEO to run the company.
Afeyan said he had been negotiating with a French entrepreneur who was, like him, a biomedical engineer. ButStphane Bancel wasn't sure he wanted to leave a stable job as CEO of an established diagnostics company for the risk of a startup with a never-before-tried idea.
Bancel was walking home across the Longfellow Bridge from Cambridge to Boston one winter night, when Afeyan called and turned on the hard sell.
Afeyan said he would never have a bigger idea to offer Bancel. If this becomes the next Genentech, "you're going to hate yourself" for not being involved, Afeyan told him, referring to the South San Francisco company that launched the entire biotechnology industry with its birth in 1976.
Later that year, Bancel signed on to run Modernaand continues to lead the company, which has now made several founders and its CEO into billionaires.
Moderna IPO(Photo: Flagship Pioneering)
The earliest seeds of Moderna
There werea few key scientific advances that led mRNA to where it is today.
Onecame from another Moderna co-founder, Robert Langer, a professor at MIT and a serial entrepreneur.
Early in his career, Langer, who had recently earned his doctorate in chemical engineering from MIT, was struggling to find a job. He didn't want to work in the oil industry, though he'd gotten 20 job offers, including fourfrom Exxon alone.
After months of searching, Dr. Judah Folkman, a passionate doctor at what is now called Boston Children's Hospital finally took a chance on him. Folkman believed he could cure cancer by cutting off the blood supply to tumorsbut he couldn't figure out how to slowly release drugs to work effectively.
Nevermind the political messenger: When it comes to COVID-19 guidance, trust the message, experts say
Langer spent years developinga way to encapsulatenucleic acids the same building blocks as in mRNA vaccines into tiny particles that could make their way into cells.
"At first people didn't think it was possible," Langer said. He published a 1976 paper showing it could be donebut still, it was a slog to get people to believe in its potential.
"After that paper came out, I must have had 10 years of people rejecting grants" to support the work, he said. (His work with Folkman provided the underlying science for the drug Avastin, which earned $7 billion in sales in 2019 and is used to treat many types of cancer as well as wet age-related macular degeneration, the leading cause of blindness in older adults.)
Langer and others made additional improvements over the years, includingadding polyethylene glycol to the surface of particles, which enabled them to survive in the body for longer. That's one of the key ingredients of Moderna and Pfizer-BioNTech's vaccines.
A subject receives a shot in the first-stage safety trial of a potential vaccine by Moderna for COVID-19 at the Kaiser Permanente Washington Health Research Institute in Seattle on March 16.(Photo: Ted S. Warren, AP)
In 2010, when Langer was one of the world's best knownbioengineers and a leader in the field of drug delivery, Rossi came to see him with a scientific insight he hoped would be the basis for starting a company. Langer introduced him to Afeyan, and the idea for LS18was born.
By the following year,Rossi moved on and the core group includedLanger, Afeyan, Dr. Kenneth Chien, a prominent cardiologist and researcher, andTimothy Springer, an immunologist at Harvard Medical School.
The four met once a week tobrainstorm, while a handful of scientists at Afeyan's Flagship Pioneering advanced their ideas in the lab.
Moderna's first real home wasan underwhelming office half basement, half ground floor just a few blocks away.
The vision from its earliest days, Langer said, was to build a "platform" that could be used as the basis for drugs, vaccinesand even tissue engineering another field he had helped pioneer.
Some Americans aren't in a rush to get a COVID-19 vaccine: Experts understand, but say there's no need to wait.
For several years, Moderna has been collaboratingon vaccine development withscientists at the National Institute of Allergy and Infectious Diseases, the agency led by Dr. Anthony Fauci.
By the end of 2018 when Moderna went public,it was the biggest initial public offering ever for a biotech company, though shares fell 19% that first day as investors worried it was overpriced.
A year later the company was testing 20 different mRNA's in humans five or six times more research programs than the typical biotech.
That was enough, said Nina Deka, a senior research analyst at ROBO Global, for her fund to decide to make Moderna one of the 85 companies included in its portfolio of health care technology and innovation stocks.
Moderna had recently announced plans to develop a COVID-19 vaccine when ROBO Global decided to invest.
"Not because of what they did this year, but what they've done since the start of the company," Deka said.
With two mRNA vaccines under development, ROBO Global expected that even if Moderna's vaccine didn't succeed, the technology would advance, buoying everyone in the industry.
"It's not just vaccines. It's also cancer. It's also orphan drugs" for rare diseases, she said.
The company had just built a brand new production facility in the Boston suburb of Norwood, and it was using advanced artificial intelligence to direct its research, which ROBO Global appreciated,Deka said.
Plus, it was breaking speed records with its candidate COVID-19 vaccine.
"The next question is," Deka said,"if they can do this quickly, what else can they do?"
Contact Karen Weintraub at firstname.lastname@example.org
Health and patient safety coverage at USA TODAY is made possible in part by a grant from the Masimo Foundation for Ethics, Innovation and Competition in Healthcare. The Masimo Foundation does not provide editorial input.
Sirnaomics to Initiate Phase I Study of STP705 in Treatment of Primary and Metastatic Liver Cancer | DNA RNA and Cells | News Channels -…
Posted: December 7, 2020 at 5:00 pm
DetailsCategory: DNA RNA and CellsPublished on Friday, 04 December 2020 14:55Hits: 1020
GAITHERSBURG, MD, USA and SUZHOU BIOBAY, China I December 3, 2020 I Sirnaomics, Inc., a biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against cancer and fibrotic diseases, announced today that the company has received feedback from the U.S. Food and Drug Administration (FDA) and may now proceed with a planned Phase I clinical study of its leading drug candidate, STP705, for treatment of multiple types of liver cancer.
The FDA has provided valuable feedback on the company's proposed trial design for a "Phase 1 Multicenter, Open-Label, Dose Escalation Study and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of STP705 Administered Intratumorally in Cholangiocarcinoma, Hepatocellular Carcinoma or Liver Metastases in Subjects With Advanced / Metastatic or Surgically Unresectable Solid Tumors Who Are Refractory to Standard Therapy." The first patient is expected to be enrolled in the study in the first quarter of 2021. STP705 is a small interfering RNA (siRNA) therapeutic that utilizes a proprietary polypeptide nanoparticle (PNP)-enhanced delivery system to inhibit expression of TGF-1 and COX-2 in targeted tissue and cells. Preclinical animal models have demonstrated its effective anti-tumor activity for treatments of cholangiocarcinoma and hepatocellular carcinoma.
"Receiving the required feedback from the FDA now permits us to proceed with this Phase Istudy that represents an important step forward in demonstrating the broader clinical utility of our siRNA therapeutic candidates," said Patrick Y. Lu, PhD, Sirnaomics' Founder and CEO. "Liver cancer treatment remainsacritical unmet need globally and especially in Asian countries. Ourclinical strategy leveraging STP705's FDA Orphan Drug designation for the treatment of cholangiocarcinoma and hepatocellular carcinoma will potentially be highly beneficial to patients suffering these life threatening diseases in both the US and Asia. We are anticipating that this clinical study will contribute to the expanding clinical evidence supportingextensivetherapeutic potential of STP705 against various cancers."
"Liver cancer continues to be a devastating disease for patients with high mortality and high unmet medical need," stated Michael Molyneaux, MD, Sirnaomics' Chief Medical Officer. "This disease fits with Sirnaomics mission to bring lifesaving drugs to patients with severe debilitating medical illness. We hope to gain important insight into the potential safety and efficacy of STP705 in this Phase I trialand we expect to build on the data from this study to expand into other oncology indications."
About Liver Cancer
Liver cancer is a global health problem, with liver neoplasms representing the second-most frequent cause of cancer-related death. There are many different types of liver cancers including hepatocellular carcinoma (HCC), cholangiocarcinoma (CCA), liver angiosarcoma, hepatoblastoma and others. Additionally, liver is a highly metastasis-permissive organ. It is the most frequently afflicted organ by metastasis and liver metastases are much more common than primary hepatic tumors. The distinctive biology of the liver renders it intrinsically susceptible to metastases. The true prevalence of liver metastasis is unknown, but between 30% and 70% of patients dying of cancer have liver metastases and most patients with liver metastases will die of their disease.
STP705 and Liver Cancer
Over expressions of TGF-1 and COX-2 have been well-characterized as playing key regulatory roles in tumorigenesis. TGF- is produced by different liver cells and is demonstrated to induce tumor cell migration and survival. TGF- has been found to be overexpressed in metastatic HCC tissues. Overexpression of TGF- is generally accepted to be associated with metastasis and poor prognosis. COX-2 is reported to be highly expressed in cancer stem cells and promotes cell migration in HCC cell lines. Additionally, inhibition of COX-2 suppresses cell migration and induces apoptosis. As such TGF-1 and COX-2 are excellent therapeutic targets for treatment of liver cancer.
STP705 is composed of two siRNA oligonucleotides targeting TGF-1 and COX-2 mRNA respectively and formulated in nanoparticles with a proprietary Histidine-Lysine Co-Polymer (HKP) peptide. Each individual siRNA has demonstrated the ability to inhibit the expression of their target mRNA and combining the two siRNAs produces a synergistic effect that diminishes pro-fibrogenic, pro-inflammatory, and pro-tumorigenic factors. Sirnaomics has completed numerous pre-clinical studies that demonstrate that inhibition of TGF-1 and COX-2 is expected to result in the inhibition of tumor growth and provide an alternative approach for the treatment of various liver cancers. Molecular analyses of the effects of administering the combination demonstrated that the inhibition of these targets had effects on downstream gene products associated with numerous oncology targets. Additional immunohistochemistry and image analyses of the liver and tumor tissues demonstrated that animals treated with STP705 resulted in increased CD4+ and CD8+ T cell infiltration within the tumor microenvironment. Using STP705 for treatments of hepatocellular carcinoma and cholangiocarcinoma have been designated as Orphan Drug indications by U.S. FDA. STP705 has also been evaluated in a Phase IIa clinical trial for treatment of Non-melanoma skin cancer.
About Sirnaomics, Inc.
Sirnaomics, Inc., a leading privately held biopharmaceutical company for discovery and development of RNAi therapeutics, is a Delaware corporation headquartered in Gaithersburg, Maryland, USA, with subsidiaries in Suzhou and Guangzhou, China. The Company's mission is to develop novel therapeutics to alleviate human suffering and advance patient care in areas of high unmet medical need. The guiding principles of the company are: Innovation, Global Vision with a Patient Centered focus. Members of the senior management team have a combined experience in the biopharmaceutical industry, spanning clinical development, regulatory, financial and business management in both the USA and China. The company is supported by funding from institutional investors, corporate partnerships and government grants. Sirnaomics has developed a strong portfolio of intellectual property with an enriched product pipeline. The therapeutic areas of focus include oncology, anti-fibrotic, anti-viral and metabolic therapeutics. Learn more at http://www.sirnaomics.com.
Trump was one of the first 10 patients to get an experimental COVID-19 treatment under special use – Yahoo News
Posted: October 8, 2020 at 9:51 am
A car with US President Trump drives past supporters in a motorcade outside of Walter Reed Medical Center in Bethesda, Maryland on October 4, 2020. - US President Donald Trump drove past supporters outside the hospital where he was being treated for Covid-19, after announcing on Twitter a "suprise visit" to his backers. ALEX EDELMAN/AFP via Getty Images
Ahead of President Donald Trump's Monday discharge from the care of Walter Reed Medical Center, where hehad been treated forthree days for symptoms of COVID-19, came atweet.
"Don't be afraid of Covid," the presidentclaimed, inpart because the country had developed "some really great drugs."
However, the president himself who once suggested injecting household disinfectants to treat the deadly disease had just become one of thefirst 10 patients granted anextraordinarily rare level of access toan experimental antibody infusion to combathis COVID-19 infection, Salon hasconfirmed.
The treatment, a cocktail of human antibodies and anti-bodies cloned from stem cells, was manufactured by Regeneron. The pharmaceutical company onlyannouncedthe results of a phase 1/2/3 trial onSept. 29, or two days before the president tested positive. The treatment, which is still pending approval from the Food and Drug Administration,proved most effective for patients with weak immune systems.
Homicidal negligence: Trump admits on tape that he hid "deadly" threat of coronavirus from public
Watchdog questions why Wells Fargo reported giving only one large PPP loan to a Black-owned business
Hours afterreceiving the treatment on Friday, Trump was flown from the White House to Walter Reed Medical Center. The White House saidat the time that the president had"mild symptoms." Trump's personal physician, Dr. Sean Conley, later acknowledged that he exhibited low oxygen levels and a fever.
But Conley would not disclose the results of Trump's lung scans, only saying they showed "expected findings." Experts noted that Conley did not say the president's lungs appeared healthy,leaving open the possibility ofinflammation or pneumonia.
Trump returned to the executive mansion three days later. After a balcony photo-op appearance, during which time his breathing appeared labored, the president remains at 1600 Pennsylvania Ave. Conley says Trump reports no symptoms medically different from "showing signs," which are noticed and reported by an attending physician.
After his experience at Walter Reed, Trump declared that Americans should not let the coronavirus, which has killed more than 210,000 people in the U.S. over the last seven months, "dominate your life."
Outside of clinical trials, almost no American has access to the treatments which were available to the president.The Food and Drug Administration limits compassionate use ("expanded access")to patients with "animmediately life-threatening condition or serious disease or condition" when "no comparable or satisfactory" alternativesare available.
Patients often wait for approval, which can includean involved review and regulatory processbetween the patient, the physician, the pharmaceutical company and the government. Typically, companies grant compassionate use free of charge, but other monoclonal antibodies currently on the market cost thousands of dollars.
"All we can say is that they asked to be able to use it, and we were happy to oblige," RegeneronCEO Dr. Leonard Schleifer toldThe New York Times. Though Trump was not the first patientgranted expanded access to the drug, Schleifer said, "When it's the president of the United States, of course, that gets obviously gets our attention."
"Presidential medicine is and has been unique," Arthur L. Caplan, professor of medical ethics at the N.Y.U. Grossman School of Medicine, toldThe Times. "If his doctors think an intervention might be helpful, and if that judgment is confirmed by outside experts they talk to and if things look dire or serious, then the president will get access to any and all agents."
Schleiferhas been a member atTrump's Westchester, N.Y., golf club,and his companytook$450 million in federalfunding this summer from Operation Warp Speed, which is the administration's moonshot projectto fast-trackCOVID-19 vaccines andtreatments, according toCNN Business.
"Len and President Trump are acquaintances from both living in the Westchester area for many years but didn't have any regular contact until this year, when they've discussed matters around COVID on occasion," a Regeneron spokesperson told CNN Business.
Schleifer is an active political donor, who predominantly gives to Democratic candidates. In 2016, Schleifergave more than $55,000 to committees supporting Hillary Clinton, but he has not yet donated to Democratic nominee Joe Biden, per FEC records. Hisson, Adam,lost a Democratic primary bid this summer for New York's 17th Congressional District.
"We don't share details on who has/hasn't submitted a compassionate use request, but as we've stated, only a small number of these requests have been approved forrareand exceptional circumstances, and that will continue to be the case," a Regeneron spokesperson told Salon in an email.
The spokesperson said the company was notaware of any side effectsoccurring in compassionate use cases and referred Salon to the FDA. The FDA did not reply to Salon's requests for comment.
In order to qualify for compassionate use, the FDA says, patients must meet a number of requirements: the disease or condition must be seriousor "immediately" life-threatening;there can be "no comparable or satisfactory alternative therapy to diagnose, monitoror treat the disease or condition"; clinical trials must be out of the question; potential benefitsmust justifypotential risks; and the treatment must not interfere with clinicaltrials that could supportproductdevelopment "or marketing approval for the treatment indication."
Given its extremely limited supply, Schleifer told CNBC that the international headlines put his company in a "very tough situation."
"Giving it to [Trump] or to others who might not be able or don't qualify for clinical trials is the right use of compassionate use. That's for small numbers of people, for these exceptions,"he said. "We want everybody to be potentially able to benefit. We understand we don't make that decision. This is a decision the FDA has to make."
Through no fault of Regeneron's own, however, the company may have harnessed one of the most powerful marketing platforms on the planet Trump's Twitter feed.
Fox News Geraldo Rivera criticizes Trump for not wearing a mask: "This disease kills old people!"
Kellyanne Conway curses out daughter in TikTok video: Youve lied about your own f*cking mother"
"They gave me Regeneron. It's called Regeneron," the president said in a Wednesday video published tohis feed, erroneouslynaming the drug company instead of its treatment."And other things, too. But I think this was the key. But they gave me Regeneron. And it was,like, unbelievable. I felt good immediately."
Trump claimed that he had "authorized" the treatment.However,it wasunclear what steps, if any, had been taken to expand its availabilityto more Americans.
Posted: at 9:51 am
It successfully launched on an Antares rocket from Virginia Space's Mid-Atlantic Regional Spaceport at NASA's Wallops Flight Facility.
Toilets in space
Removing gravity from the equation means that nothing functions in space the way it does on Earth -- toilets included.
While the existing toilets are reliable, the new design is more user-friendly and easier to maintain, Morgan said.
The new compact toilet includes a funnel and hose for urine and a seat for bowel movements. In the absence of gravity, air flow pulls these away from the body.
The new design begins air flow automatically as soon as the lid is lifted on the toilet. This also helps control odor.
The new design is about 65% smaller and 40% lighter, with more efficient waste management and storage. This will come in handy as more crew members come to stay on the space station with the addition of the Commercial Crew Program, which can carry more astronauts in a single launch.
Astronaut feedback from using the existing toilets on the space station went into this new design, which is more ergonomic, requires less cleanup, is easier to maintain, has parts that are durable and is resistant to corrosion. The funnel and seat of this design can also be used simultaneously, which was incorporated
after feedback from female astronauts.
"The toilet is a great example of including all the feedback from various crewmembers," Meir said. "This better accounts for those, much easier for everyone to use up there."
The existing toilet was designed some time ago when there were few, if any, female astronauts staying on the space station. This design now better accounts for anatomical differences between men and women, Meir said.
Since water is a key factor of the life support systems on the space station, as well as those that will be used in future exploration of the moon and Mars, the astronauts' urine does not go to waste.
"We recycle about 90% of all water-based liquids on the space station, including urine and sweat," Meir said in a separate statement. "What we try to do aboard the space station is mimic elements of Earth's natural water cycle to reclaim water from the air. And when it comes to our urine on ISS, today's coffee is tomorrow's coffee!"
The toilet's urine transfer system will pretreat the urine and feed it into a regenerative system that recycles the water.
A second toilet like this will be installed in the Orion spacecraft to be used for the Artemis II flight test, which will send astronauts on a 10-day mission beyond the moon and back in 2023.
A virtual reality spacewalk
If you've ever watched astronauts conducting a spacewalk outside of the space station and wanted to know what it was like, a new camera will capture that experience in immersive 3D.
Felix & Paul Studios, helmed by creative directors Felix Lajeunesse and Paul Raphael, have partnered with the ISS National Lab in its ongoing "ISS Experience" virtual reality series. They previously sent up a camera in 2018 to document life inside the space station.
Now, the team, along with commercial partner Nanoracks, has modified a camera to withstand exposure to space and handle variable light exposure as the station passes through various sunrises and sunsets each day.
The camera will be mounted on the robotic arm Canadarm2 and film a spacewalk, from beginning to end, as well as the exterior of the space station and perspectives of the Earth.
These will be included in the final episodes of the series "Space Explorers: The ISS Experience." It will be available to watch on multiple platforms.
"This new EVA camera will enable that 3D immersive experience during a spacewalk," Meir said. "Spacewalks are the most challenging things that we do, both mentally and physically, and also the most exciting. You're out there in your own little spacecraft looking down on Earth with nothing between the void of space except for the thin visor of your helmet."
Meir participated in multiple spacewalks, including the first all-female spacewalk with fellow NASA astronaut Christina Koch in 2019.
Taking this camera outside of the space station after seeing the power of it inside the station will really make people feel like they're there, Morgan said. He also sees potential for the camera to be used as a way to train astronauts as they prepare for spacewalks.
When gravity isn't a factor
A variety of scientific experiments have taken place on the space station because the orbiting laboratory provides a unique environment that removes gravity as a factor.
One of the growing areas of research on the space station includes therapies for diseases like cancer.
Kernal Biologics is sending up an investigation that will use the microgravity environment to improve messenger RNA immunotherapy treatment for leukemia. Messenger RNA, or mRNA, is in all human cells to help create proteins, but it can differ in cancer cells compared to healthy cells.
Under the normal gravity conditions we experience on Earth, drugs tested for this are onco-selective, which means they can identify cancer cells from healthy cells and destroy the malignant cells. The microgravity environment of the space station can cause changes in mRNA. If these drugs are also effective in the microgravity environment, they could provide safer, more affordable and effective therapies for leukemia and other cancer treatments.
Other things are possible on the space station that simply can't happen on Earth, like cool diffusion flames. These flames, which burn at temperature below 752 degrees Fahrenheit, were first witnessed in an experiment on the space station in 2012. They don't exist on Earth.
"All flames have cool temperature chemistry that's going on," said Peter Sunderland, investigator of the experiment and a professor at the University of Maryland's A. James Clark School of Engineering. "Gravity is ubiquitous in combustion because hot gases rise, and a candle flame is narrow and tall. In microgravity, you get a much larger and spherical flame."
His experiment, funded by the National Science Foundation, could have implications for the efficiency of combustion engines and even help reduce emissions on Earth. During the investigation, researchers will look to observe spherical flames in microgravity to better understand the physics of cool diffusion flames.
Multiple experiments by students sponsored by the ISS National Lab also are included in the launch.
Researchers and graduate students at the University of Adelaide in Australia have an experiment that will help determine how microgravity and radiation impact the stability of pharmaceutical tablets. This will take place inside the space station, and a second experiment will occur in Alpha Space's MISSE (Materials International Space Station Experiment) Flight Facility on the exterior of the space station.
The University of Georgia is sending up its Spectral Ocean Color Satellite, a CubeSat, or miniaturized satellite, that can capture images used to monitor water quality and determine the health of ecosystems like coastal wetlands. Once it has arrived, this loaf-size satellite will launch from the space station on a Nanoracks deployer.
"The ISS National Lab takes great pride in working with our education and implementation partners to enable student researchers to take their science, engineering and technology questions to space far beyond their normal lab settings on Earth," said Michael Roberts, interim chief scientist at the Center for the Advancement of Science in Space and manager of the ISS National Lab.
"By collaboration with educators to support education projects on the space station, we hope to instill in students a lifelong interest in science and inspire them to pursue exciting career opportunities available in STEM fields."
See the article here:
New toilet, a VR camera and science experiments are heading to t - KAKE
Posted: August 26, 2020 at 7:57 pm
EASTON ShoreRivers has announced the receipt of a Maryland Department of Natural Resources Trust Fund grant to complete two large ecological restorations on the Eastern Shore that will significantly reduce nutrient and sediment pollution entering local rivers.
In the Wye River watershed, ShoreRivers will restore 29 acres of marginal cropland to ponds, wetlands, and forest.
In the Sassafras River watershed, ShoreRivers will restore 16 acres of floodplain and 4,800 feet of stream. This project will result in the complete restoration of the entire length of the stream, from a headwater agricultural ditch to the main stem of the Sassafras.
The projects are slated to begin this fall and be completed by December 2021.
Wye River Restoration at Chesapeake College
The Chesapeake College Agriculture to Ecosystem project will convert 28.72 acres of an agricultural field with a badly incised ditch that drains nutrient and sediments to the Wye East River.
The land will be removed from production, converted into two ponds, a series of wetland cells with habitat islands, planted infiltration berms and approximately 13.5 acres of tree plantings. The campus of Chesapeake College is located at the headwaters of the Wye East River.
This site will undergo a total conversion from an agricultural field to high quality wetland and forest habitat, all in view of heavily trafficked U.S. Route 50. This project will complement ShoreRivers regenerative stormwater conveyance project installed on a separate stream on the Chesapeake College campus, in addition to bioretentions, tree plantings, wildflower meadows, switchgrass buffers and a wetland that have been installed throughout the campus.
The project will also incorporate a walking path to allow students to use the project as an outdoor laboratory.
Sassafras River Stream Restoration
The project in the Sassafras River watershed will restore 16 acres of floodplain wetlands and 4,800 feet of a headwater stream in the upper Sassafras. Combined with a recently completed restoration of 3,800 feet of stream also funded by Maryland DNR, this project represents 8,000 consecutive feet of stream restoration beginning in a headwaters agricultural ditch and flowing all the way to the main stem of the Sassafras River.
This restoration site is directly downstream of a ShoreRivers sampling site that historically has the highest monitored nutrient concentrations in the non-tidal Sassafras. The drainage is mainly agricultural but includes 43 acres of state and county roadways.
Heavy stormflow runoff events have incised the stream channel with steep, eroding banks that are disconnected from its historic floodplain and subsequently unable to disperse stormflow energy, continually increasing the severity of bank erosion and over-widening of the channel.
This restoration, designed by Ecotone Ecological Restoration in consultation with ShoreRivers, goes beyond the consideration of nutrient processing and sediment storage, placing significant emphasis on promoting quality of in-stream and floodplain habitat, ecological uplift and biodiversity.
The restoration will promote higher dissolved oxygen levels within the stream system and lower water temperatures. This, along with connectivity of the floodplain, restoration of groundwater hydrology, seep habitat and vernal pool wetlands, will provide critical habitat for a range of amphibians, reptiles, insects and fish, and improve fish passage through the system to the Sassafras River headwaters.
CRISPR cows could boost sustainable meat production, but regulations and wary consumers stand in the way – Genetic Literacy Project
Posted: at 7:57 pm
When Ralph Fisher,a Texas cattle rancher, set eyes on one of the worlds first cloned calves in August 1999, he didnt care what the scientists said: He knew it was his old Brahman bull, Chance, born again. About a year earlier, veterinarians at Texas A&M extracted DNA from one of Chances moles and used the sample to create a genetic double. Chance didnt live to meet his second self, but when the calf was born, Fisher christened him Second Chance, convinced he was the same animal.
Scientists cautioned Fisher that clones are more like twins than carbon copies: The two may act or even look different from one another. But as far as Fisher was concerned, Second Chance was Chance. Not only did they look identical from a certain distance, they behaved the same way as well. They ate with the same odd mannerisms; laid in the same spot in the yard. But in 2003, Second Chance attacked Fisher and tried to gore him with his horns. About 18 months later, the bull tossed Fisher into the air like an inconvenience and rammed him into the fence. Despite 80 stitches and a torn scrotum, Fisher resisted the idea that Second Chance was unlike his tame namesake,telling the radio program This American Life that I forgive him, you know?
In the two decades since Second Chance marked a genetic engineering milestone, cattle have secured a place on the front lines of biotechnology research. Today, scientists around the world are using cutting-edge technologies, fromsubcutaneous biosensorstospecialized food supplements, in an effort to improve safety and efficiency within the$385 billion global cattle meat industry. Beyond boosting profits, their efforts are driven by an imminent climate crisis, in which cattle play a significant role, and growing concern for livestock welfare among consumers.
Gene editing stands out as the most revolutionary of these technologies. Although gene-edited cattle have yet to be granted approval for human consumption, researchers say tools like Crispr-Cas9 could let them improve on conventional breeding practices and create cows that are healthier, meatier, and less detrimental to the environment. Cows are also beinggiven genesfrom the human immune system to create antibodies in the fight against Covid-19. (The genes of non-bovine livestock such as pigs and goats, meanwhile, have been hacked togrow transplantable human organsandproduce cancer drugs in their milk.)
But some experts worry biotech cattle may never make it out of the barn. For one thing, theres the optics issue: Gene editing tends to grab headlines for its role in controversial research and biotech blunders. Crispr-Cas9 is often celebrated for its potential to alter the blueprint of life, but that enormous promise can become a liability in the hands of rogue and unscrupulous researchers, tempting regulatory agencies to toughen restrictions on the technologys use. And its unclear how eager the public will be to buy beef from gene-edited animals. So the question isnt just if the technology will work in developing supercharged cattle, but whether consumers and regulators will support it.
Cattle are catalysts for climate change. Livestockaccount for an estimated 14.5 percent of greenhouse gas emissions from human activities, of which cattle are responsible for about two thirds, according to the United Nations Food and Agriculture Organization (FAO). One simple way to address the issue is to eat less meat. But meat consumption is expected to increasealong with global population and average income. A 2012reportby the FAO projected that meat production will increase by 76 percent by 2050, as beef consumption increases by 1.2 percent annually. And the United States isprojected to set a recordfor beef production in 2021, according to the Department of Agriculture.
For Alison Van Eenennaam, an animal geneticist at the University of California, Davis, part of the answer is creating more efficient cattle that rely on fewer resources. According to Van Eenennaam, the number of dairy cows in the United Statesdecreasedfrom around 25 million in the 1940s to around 9 million in 2007, while milk production has increased by nearly 60 percent. Van Eenennaam credits this boost in productivity to conventional selective breeding.
You dont need to be a rocket scientist or even a mathematician to figure out that the environmental footprint or the greenhouse gases associated with a glass of milk today is about one-third of that associated with a glass of milk in the 1940s, she says. Anything you can do to accelerate the rate of conventional breeding is going to reduce the environmental footprint of a glass of milk or a pound of meat.
Modern gene-editing tools may fuel that acceleration. By making precise cuts to DNA, geneticists insert or remove naturally occurring genes associated with specific traits. Some experts insist that gene editing has the potential to spark a new food revolution.
Jon Oatley, a reproductive biologist at Washington State University, wants to use Crispr-Cas9 to fine tune the genetic code of rugged, disease-resistant, and heat-tolerant bulls that have been bred to thrive on the open range. By disabling a gene called NANOS2, he says he aims to eliminate the capacity for a bull to make his own sperm, turning the recipient into a surrogate for sperm-producing stem cells from more productive prized stock. These surrogate sires, equipped with sperm from prize bulls, would then be released into range herds that are often genetically isolated and difficult to access, and the premium genes would then be transmitted to their offspring.
Furthermore, surrogate sires would enable ranchers to introduce desired traits without having to wrangle their herd into one place for artificial insemination, says Oatley. He envisions the gene-edited bulls serving herds in tropical regions like Brazil, the worldslargestbeef exporter and home to around 200 million of the approximately 1.5 billion head of cattle on Earth.
Brazils herds are dominated by Nelore, a hardy breed that lacks the carcass and meat quality of breeds like Angus but can withstand high heat and humidity. Put an Angus bull on a tropical pasture and hes probably going to last maybe a month before he succumbs to the environment, says Oatley, while a Nelore bull carrying Angus sperm would have no problem with the climate.
The goal, according to Oatley, is to introduce genes from beefier bulls into these less efficient herds, increasing their productivity and decreasing their overall impact on the environment. We have shrinking resources, he says, and need new, innovative strategies for making those limited resources last.
Oatley has demonstrated his technique in mice but faces challenges with livestock. For starters, disabling NANOS2 does not definitively prevent the surrogate bull from producing some of its own sperm. And while Oatley has shown he can transplant sperm-producing cells into surrogate livestock, researchers have not yet published evidence showing that the surrogatesproduceenough quality sperm to support natural fertilization. How many cells will you need to make this bull actually fertile? asks Ina Dobrinski, a reproductive biologist at the University of Calgary who helped pioneer germ cell transplantation in large animals.
But Oatleys greatest challenge may be one shared with others in the bioengineered cattle industry: overcoming regulatory restrictions and societal suspicion. Surrogate sires would be classified as gene-edited animals by the Food and Drug Administration, meaning theyd face a rigorous approval process before their offspring could be sold for human consumption. But Oatley maintains that if his method is successful, the sperm itself would not be gene-edited, nor would the resulting offspring. The only gene-edited specimens would be the surrogate sires, which act like vessels in which the elite sperm travel.
Even so, says Dobrinski, Thats a very detailed difference and Im not sure how that will work with regulatory and consumer acceptance.
In fact, American attitudes towards gene editing have been generally positive when the modification is in the interest of animal welfare. Many dairy farmers prefer hornless cows horns can inflict damage when wielded by 1,500-pound animals so they often burn them off in apainful processusing corrosive chemicals and scalding irons. Ina study published last yearin the journal PLOS One, researchers found that most Americans are willing to consume food products from cows genetically modified to be hornless.
Still, experts say several high-profile gene-editing failures in livestock andhumansin recent years may lead consumers to consider new biotechnologies to be dangerous and unwieldy.
In 2014, a Minnesota startup called Recombinetics, a company with which Van Eenennaams lab has collaborated, created a pair of cross-bred Holstein bulls using the gene-editing tool TALENs, a precursor to Crispr-Cas9, making cuts to the bovine DNA and altering the genes to prevent the bulls from growing horns. Holstein cattle, which almost always carry horned genes, are highly productive dairy cows, so using conventional breeding to introduce hornless genes from less productive breeds can compromise the Holsteins productivity. Gene editing offered a chance to introduce only the genes Recombinetics wanted. Their hope was to use this experiment to prove that milk from the bulls female progeny was nutritionally equivalent to milk from non-edited stock. Such results could inform future efforts to make Holsteins hornless but no less productive.
The experiment seemed to work. In 2015, Buri and Spotigy were born. Over the next few years, the breakthrough received widespread media coverage, and when Buris hornless descendant graced thecover of Wired magazine in April 2019, it did so as the ostensible face of the livestock industrys future.
But early last year, a bioinformatician at the FDA ran a test on Buris genome and discovered an unexpected sliver of genetic code that didnt belong. Traces of bacterial DNA called a plasmid, which Recombinetics used to edit the bulls genome, had stayed behind in the editing process, carrying genes linked to antibiotic resistance in bacteria. After the agency publishedits findings, the media reaction was swift and fierce: FDA finds a surprise in gene-edited cattle: antibiotic-resistant, non-bovine DNA,readone headline. Part cow, part bacterium?readanother.
Recombinetics has since insisted that the leftover plasmid DNA was likely harmless and stressed that this sort of genetic slipup is not uncommon.
Is there any risk with the plasmid? I would say theres none, says Tad Sonstegard, president and CEO of Acceligen, a Recombinetics subsidiary. We eat plasmids all the time, and were filled with microorganisms in our body that have plasmids. In hindsight, Sonstegard says his teams only mistake was not properly screening for the plasmid to begin with.
While the presence of antibiotic-resistant plasmid genes in beef probably does not pose a direct threat to consumers, according to Jennifer Kuzma, a professor of science and technology policy and co-director of the Genetic Engineering and Society Center at North Carolina State University, it does raise the possible risk of introducing antibiotic-resistant genes into the microflora of peoples digestive systems. Although unlikely, organisms in the gut could integrate those genes into their own DNA and, as a result, proliferate antibiotic resistance, making it more difficult to fight off bacterial diseases.
The lesson that I think is learned there is that science is never 100 percent certain, and that when youre doing a risk assessment, having some humility in your technology product is important, because you never know what youre going to discover further down the road, she says. In the case of Recombinetics. I dont think there was any ill intent on the part of the researchers, but sometimes being very optimistic about your technology and enthusiastic about it causes you to have blinders on when it comes to risk assessment.
The FDA eventually clarified its results, insisting that the study was meant only to publicize the presence of the plasmid, not to suggest the bacterial DNA was necessarily dangerous. Nonetheless, the damage was done. As a result of the blunder,a plan was quashedforRecombinetics to raise an experimental herd in Brazil.
Backlash to the FDA study exposed a fundamental disagreement between the agency and livestock biotechnologists. Scientists like Van Eenennaam, who in 2017 received a $500,000 grant from the Department of Agriculture to study Buris progeny, disagree with the FDAs strict regulatory approach to gene-edited animals. Typical GMOs aretransgenic, meaning they have genes from multiple different species, but modern gene-editing techniques allow scientists to stay roughly within the confines of conventional breeding, adding and removing traits that naturally occur within the species.
That said, gene editing is not yet free from errors and sometimes intended changes result in unintended alterations, notes Heather Lombardi, division director of animal bioengineering and cellular therapies at the FDAs Center for Veterinary Medicine. For that reason, the FDA remains cautious.
Theres a lot out there that I think is still unknown in terms of unintended consequences associated with using genome-editing technology, says Lombardi. Were just trying to get an understanding of what the potential impact is, if any, on safety.
Bhanu Telugu, an animal scientist at the University of Maryland and president and chief science officer at the agriculture technology startup RenOVAte Biosciences, worries that biotech companies willmigrate their experimentsto countries with looser regulatory environments. Perhaps more pressingly, he says strict regulation requiring long and expensive approval processes may incentivize these companies to work only on traits that are most profitable, rather than those that may have the greatest benefit for livestock and society, such as animal well-being and the environment.
What company would be willing to spend $20 million on potentially alleviating heat stress at this point? he asks.
On a windywinter afternoon, Raluca Mateescu leaned against a fence post at the University of Floridas Beef Teaching Unit while a Brahman heifer sniffed inquisitively at the air and reached out its tongue in search of unseen food. Since 2017, Mateescu, an animal geneticist at the university, has been part of a team studying heat and humidity tolerance in breeds like Brahman and Brangus (a mix between Brahman and Angus cattle). Her aim is to identify the genetic markers that contribute to a breeds climate resilience, markers that might lead to more precise breeding and gene-editing practices.
In the South, Mateescu says, heat and humidity are a major problem. That poses a stress to the animals because theyre selected for intense production to produce milk or grow fast and produce a lot of muscle and fat.
Like Nelore cattle in South America, Brahman are well-suited for tropical and subtropical climates, but their high tolerance for heat and humidity comes at the cost of lower meat quality than other breeds. Mateescu and her team have examined skin biopsies and found that relatively large sweat glands allow Brahman to better regulate their internal body temperature. With funding from the USDAs National Institute of Food and Agriculture, the researchers now plan to identify specific genetic markers that correlate with tolerance to tropical conditions.
If were selecting for animals that produce more without having a way to cool off, were going to run into trouble, she says.
There are other avenues in biotechnology beyond gene editing that may help reduce the cattle industrys footprint. Although still early in their development,lab-cultured meatsmay someday undermine todays beef producers by offering consumers an affordable alternative to the conventionally grown product, without the animal welfare and environmental concerns that arise from eating beef harvested from a carcass.
Other biotech techniques hope to improve the beef industry without displacing it. In Switzerland, scientists at a startup called Mootral areexperimenting with a garlic-based food supplementdesigned to alter the bovine digestive makeup to reduce the amount of methane they emit. Studies have shown the product to reduce methane emissions by about 20 percent in meat cattle, according to The New York Times.
In order to adhere to the Paris climate agreement, Mootrals owner, Thomas Hafner, believes demand will grow as governments require methane reductions from their livestock producers. We are working from the assumption that down the line every cow will be regulated to be on a methane reducer, he told The New York Times.
Meanwhile, a farm science research institute in New Zealand, AgResearch, hopes to target methane production at its source by eliminating methanogens, the microbes thought to be responsible for producing the greenhouse gas in ruminants. The AgResearch team isattempting to developa vaccine to alter the cattle guts microbial composition, according to the BBC.
Genomic testing may also allow cattle producers to see what genes calves carry before theyre born, according to Mateescu, enabling producers to make smarter breeding decisions and select for the most desirable traits, whether it be heat tolerance, disease resistance, or carcass weight.
Despite all these efforts, questions remain as to whether biotech can ever dramatically reduce the industrys emissions or afford humane treatment to captive animals in resource-intensive operations. To many of the industrys critics, including environmental and animal rights activists, the very nature of the practice of rearing livestock for human consumption erodes the noble goal of sustainable food production. Rather than revamp the industry, these critics suggest alternatives such as meat-free diets to fulfill our need for protein. Indeed,data suggestsmany young consumers are already incorporating plant-based meats into their meals.
Ultimately, though, climate change may be the most pressing issue facing the cattle industry, according to Telugu of the University of Maryland, which received a grant from the Bill and Melinda Gates Foundation to improve productivity and adaptability in African cattle. We cannot breed our way out of this, he says.
Dyllan Furness is a Florida-based science and technology journalist. His work has appeared in Quartz, OneZero, and PBS, among other outlets. Follow him on Twitter @dyllonline
This article was originally published at Undark and has been republished here with permission. Follow Undark on Twitter @undarkmag
Over $8M in 2020 Stem Cell Funding Awards Continue to Fuel Marylands Leading Cell Therapy Industry – BioBuzz
Posted: June 24, 2020 at 9:50 am
The Maryland Stem Cell Research Commission (The Commission) recently announced over $7M in Maryland Stem Cell Fund (MSCF) grant awards for its second round of 2020 MSCF fund recipients. The MSCF, which is a program of the Maryland Technology Development Corporation (TEDCO), has awarded $157M in funding to BioHealth Capital Region (BHCR) companies seeking to accelerate stem cell research, therapies and commercialization of products since 2007.
The $7M in new funding follows MSCFs announcement in September 2019 of over $1.3M in grants for the first cohort of 2020 recipients, bringing the total 2020 MSCF award tally to approximately $8.3M for the year. The financial awards are delivered across a wide range of areas, including clinical, commercialization, validation, launch, discovery, and post-doctoral fellowships. The first cohort of funding included three commercialization and two validation awards; the second, larger recipient pool included one clinical, one commercialization, one validation, four launches, 11 discovery, and five post-doctoral awards.
Notable BHCR MSCF recipients included:
Dr. Luis Garza of Johns Hopkins University (JHU) received a clinical grant to support clinical trials for his autologous volar fibroblast injection into the stump site of amputees. The trials are exploring ways to make the skin where a prosthetic limb meets the stump site tougher and less irritable to the wearer. Skin irritation is a major issue for those with prosthetic limbs and is often a cause for individuals to stop wearing their prosthesis.
Vita Therapeutics, a company that spun out of JHU, was awarded a 300K MSCF grant to support the commercialization of the companys satellite stem cell therapy for limb-girdle Muscular Dystrophy. According to the National Organization for Rare Disorders (NORD), Limb-girdle muscular dystrophies (LGMD) are a group of rare progressive genetic disorders that are characterized by wasting (atrophy) and weakness of the voluntary muscles of the hip and shoulder areas (limb-girdle area). Vita Therapeutics is led by CEO Douglass Falk, who is a JHU alum.
Jamie Niland, VP of Baltimore, Marylands Neoprogen Inc. received part of $892,080K in funding that was part of MSCFs first 2020 grant round. Jamie is the son of Bill Niland, Neoprogens current CEO and the former leader of Baltimore, Maryland life science community anchor Harpoon Medical, which was acquired by Edwards Scientific in 2017. The award was for Neoprogens neonatal cardiac stem cells for the heart tissue regeneration program.
Dr. Brian Pollok of Rockville, Marylands Propagenix, Inc., was also the recipient of a commercialization award for his Apical Surface-Outward (ASO) airway organoids, which is a potential novel cell system for drug discovery and personalized medicine. Propagenix develops innovative new technologies that address unmet needs in epithelial cell biologyfor applications in life science research as well as in precision diagnostics, and next-generation therapeutics such as immune-oncology, tissue engineering, and regenerative medicine, according to the companys website.
In addition, Dr. Ines Silva, R&D Manager of REPROCELL, USA received an MSCF commercialization grant for its work on building a commercial neural cell bank from patient-derived induced pluripotent stem cells. REPROCELL was founded in Japan in 2003 and acquired BioServe in Beltsville, Maryland in 2014.
Dr. Sashank Reddy, the founder of JHU startup LifeSprout and Medical Director, Johns Hopkins Technology Ventures Johns Hopkins University, received a portion of the $1,334,462 distributed for launch grants in 2020. The grant will go to support the launch of regenerative cell therapies for soft tissue restoration. LifeSprout recently closed a $28.5M seed round.
Past MSCF grant recipients include Frederick, Marylands RoosterBio, Inc. and Theradaptive, Inc., and Baltimore, Marylands Gemstone Biotherapeutics and Domicell, Inc., among others.
TEDCOs MSRF program continues to lend its deep support and ample funding to build and grow Marylands burgeoning and exciting regenerative medicine industry. Well be keeping a close eye on these companies as they grow and make future contributions to the thriving BHCR biocluster.
Steve has over 20 years experience in copywriting, developing brand messaging and creating marketing strategies across a wide range of industries, including the biopharmaceutical, senior living, commercial real estate, IT and renewable energy sectors, among others. He is currently the Principal/Owner of StoryCore, a Frederick, Maryland-based content creation and execution consultancy focused on telling the unique stories of Maryland organizations.